Bacterial genetic resistance to antibiotics is a major concern, making infections difficult to treat. To combat this, various drug delivery systems have been utilized. However, none of the strategies are effective due to limitations such as multiple dosage requirements, ineffective treatment, and reduced shelf life. Hence, there is a need for a robust novel antibiotic drug delivery system. This invention aims to resolve the shortcomings with a polymersome nanocarrier system. 



Technology Overview

This work focuses on developing new nanobiotechnologies to combat antibiotic-resistant bacterial infections. The current invention describes a strategy for treatment with silver and antibiotics, where the drugs are formulated with a silver-nanoparticle embedded polymersome nanocarrier made from amphiphilic diblock co-polymers and silver ions. The di-block copolymer is made from methoxy-poly-(ethylene glycol) (mPEG) and poly-D-L-lactic acid (PDLLA). The silver particles are localized in the hydrophobic membranes of the nanocarrier and the antibiotic drug in its aqueous core provide a dual-action mechanism for killing bacteria. 




  • Homogenous particle size, narrow size range and increased stability of nanoparticles due to novel synthesis method 
  • Combination drug therapy to combat complex infections 
  • Encapsulation inside nanosomes can reduce nanoparticle cytotoxicity. 
  • Ideal particle size to avoid clearance by the immune system 
  • Long-lasting drug release (over a few weeks) as encapsulation reduces dose release 
  • Effective therapy against drug-resistant infections 
  • Reduced antibiotic degradation hence, improved shelf life 
  • Reduced dosing frequency 



  • The polymersome nanocarriers offer a platform for drug delivery for treatment of- 
    • Life-threatening infections especially related to antibiotic-resistant bacteria such as MRSA 
    • Persistent infections 
  • Nanocarriers could be used as coatings for medical device or implants to reduce infections 



  • License
  • Partnering
  • Research collaboration
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
Thomas Webster
Benjamin Geilich
Medical Device